Object: Pexelizumab is a humanized monoclonal antibody inhibiting C5 complement. It has been postulated to improve outcomes in patients undergoing coronary artery bypass surgery and urgent reperfusion therapy for ST elevation myocardial infarction. We aimed at evaluating the risk/benefit profile of pexelizumab (bolus 1 infusion) versus placebo on top of current approaches in the management of patients with ST elevation myocardial infarction or undergoing coronary artery bypass.
Results: Seven trials were included (15, 196 Conclusion: Our data ruled out the hypothesis of any benefit of adding pexelizumab on top of currently available therapies for ST elevation myocardial infarction. However, pexelizumab reduces the risk of death in patients undergoing coronary artery bypass grafting. I schemic heart disease is a major public health problem both in Western and in developing countries, with 7 million persons in the United States currently affected. 1 Despite improvements in diagnosis, pharmacologic therapy, and surgical therapy, ischemic heart disease remains one of the leading causes of mortality. 1 In the past few years, therapeutic strategies aimed at modifying the role of complement in ischemic heart disease have received increasing attention. Not only is the complement system activated by inflammation, but it also plays an integral role in the propagation of inflammation, the coagulation cascade, and apoptosis. Once the terminal components of complement have been activated, they drive the cleavage of C5 into C5a, a powerful anaphylatoxin and proinflammatory mediator, and C5b, which leads to formation of C5b-9, the terminal membrane attack complex (MAC). MAC is a transmembrane channel involved in thrombosis and inflammation, which also causes direct tissue injury through osmotic lysis. 2 Pexelizumab is a recombinant humanized single-chain monoclonal antibody to C5 that blocks the conversion of C5 to C5a and C5b-9, thus preventing the formation of MAC. It has been studied in a randomized fashion, in multiple studies and settings, primarily ST elevation myocardial infarction (STEMI) 
Methods

Study Selection
BioMedCentral, CENTRAL, mRCT, and PubMed were searched without language restrictions (updated to October 2007), according to an established method (see appendix for the electronic search algorithm). 3 Pertinent trials were also searched in major recent international cardiology meetings. References of original and review articles were cross-checked.
Inclusion/Exclusion Criteria
Specifically, inclusion criteria were (1) randomized allocation, (2) controlled comparison of pexelizumab (2 mg/kg bolus plus 0.05 mg $ kg
21
$ h 21 20-24-hour infusion) versus placebo in the setting of ischemic heart disease, and (3) intention-to-treat analysis. Exclusion criteria were (1) an equivocal treatment allocation process, (2) significant imbalances in major baseline characteristics among study groups, and (3) incomplete (,80%) follow-up.
Data Extraction and End Points of Interest
Four trained and independent reviewers (L.T., W.J.V.G., G.B.Z., and P.A.) performed data abstraction blindly. Divergences were resolved by consensus. The end point of interest was the combined rate of major adverse events (MAEs), defined as all-cause death, nonfatal acute myocardial infarction (AMI), or nonfatal thromboembolic stroke. Additional analyses were carried out according to clinical settings, single end points, and the rate of congestive heart failure (CHF). All data referred to the longest follow-up available in each trial.
Data Synthesis and Analysis
Review Manager 4.2.5 4 and SPSS 11.0 (SPSS, Inc, Chicago, Ill) were used. Review Manager is a comprehensive statistical and reviewing program, developed and maintained by the Cochrane Collaboration, which includes ad hoc statistical tools for pooled estimate calculations, according to several methods.
Statistical Analyses
Odds ratios with 95% confidence intervals (95% CI) were used as summary statistics. Binary outcomes from individual studies were combined with both DerSimonian and Laird 5 random-effect model and fixed-effect model, according to an intention-to-treat analysis. We also carried out the z test where z 5 estimated effect size/standard error of the estimated effect size, and the odds ratio (OR) considered on the log scale. Inasmuch as log(OR) has a unimodal distribution, the reported z values were analyzed to obtain a 2-tailed ''P,'' and hypothesis testing results were considered statistically significant at the .05 level. 6 As per protocol, we calculated the number needed to treat to prevent an MAE as the inverse of random effect ORs.
We computed Cochrane Q heterogeneity test (H) by summing the squared deviations of each study's estimate from the overall meta-analytic estimate, weighting each study's contribution in the same manner. Heterogeneity was considered significant at ''P for H'' , .10. 6 According to Higgins and associates, 7 we used the Q together with the resulting degrees of freedom (df) to calculate the proportion of variation resulting from heterogeneity: (Inconsistency:
The degree of inconsistency among studies (I 2 ) was estimated with scores of less than 25%, between 25% and 75%, and more than 75%, representing, respectively, low, moderate, or high inconsistency. 7 The internal validity of the included trials was appraised according to the Cochrane Collaboration criteria, that is, judging the risk of selection, performance, attrition, and adjudication biases; the risk of bias was expressed as low (A), moderate (B), or high (C); incomplete reporting leading to inability to ascertain the underlying risk of bias was scored as D. Allocation concealment was distinguished as adequate (A), unclear (B), inadequate (C), or not used (D). 6 Sensitivity analysis was performed by excluding trials one at a time, from those with the lowest to those with the highest quality score, to assess the contribution of each study to the pooled estimates. 6 The likelihood of publication bias was assessed graphically by generating a funnel plot for the combined end point of MAEs and mathematically by means of the test derived by Egger and associates 8 (P for significant asymmetry , 0.1).
This study is inspired by good practice guidelines, 9 including those from the Cochrane Collaboration and the Quality of Reporting of Meta-analyses (QUOROM) statement. 10 
Results
Search Results
From 44 potentially relevant citations, our search identified 6 studies that randomized a total of 15,196 patients. [11] [12] [13] [14] [15] [16] [17] Two trials investigated the efficacy of pexelizumab as adjunctive therapy to primary percutaneous intervention in AMI (STEMI), 11, 12 3 in the setting of CABG surgery, [13] [14] [15] 1 in the setting of CABG surgery combined with aortic valve replacement, 16 and 1 in the setting of patients with AMI treated with fibrinolysis 17 ( Figure 1 ). Four trials 11,13,14 randomized patients to placebo or pexelizumab bolus plus 24-hour infusion and 3 trials 12, [15] [16] [17] to placebo, pexelizumab bolus only, and pexelizumab bolus plus 24-hour infusion, but we excluded the bolus-only arms, as per protocol, to avoid further heterogeneity.
Study Characteristics and Quality Assessment
The main characteristics of the 6 trials are listed in Table 1 . Generally, all studies were of good quality, that is, at low risk of bias with adequate allocation concealment. One study has been published only as an abstract presentation. 15 
Overall Quantitative Findings
The pooled estimates by the random effect model did not differ significantly from those obtained by the fixed effect model. The presented results are according to the former. In the overall analysis, no differences were found between pexelizumab and placebo for the risk of MAE (OR 0. Table 2) .
CABG surgery. In 4 trials including a total of 8177 patients, [13] [14] [15] [16] 
Assessment of Heterogeneity
Significant heterogeneity with moderate/high inconsistency was found in the analyses for MAE and death both overall and in the setting of STEMI patients, but not in the setting of CABG surgery. It is conceivable that such findings reflect the disparate results of the APEX AMI 11 and COMMA 12 trials. On sensitivity analysis, the exclusion of any single trial did not substantively alter the overall results. We also performed a further sensitivity analysis adding one at a time the bolus-only arms, initially excluded as per protocol, to minimize inconsistency and heterogeneity. The results did not significantly differ from the analyses done by excluding the bolus arms.
Assessment of Possible Biases
The funnel plot for all studies according to the risk of MAE and death ( Figure 5 ) showed an overall symmetry, further confirmed by Egger's test as ''P for asymmetry'' was 0.985 and 0.844, respectively, thus excluding possible publication or ''small study'' bias. Our predefined protocol was to exclude studies with a follow-up less than 80%; however, none of the retrieved citations was excluded for this reason.
Discussion
Inflammation plays a key role in atherosclerosis and plaque rupture leading to AMI, as well as in microcirculatory dysfunction after ischemia and reperfusion. Complement activation has a pivotal role in this inflammatory response. Experimental models of myocardial ischemia and reperfusion have demonstrated that inhibition of the C5 component of complement results in reduced infarct size and less apoptosis. 2 In the PRIMO-CABG trial, pexelizumab significantly reduced the amount of myocardial damage. 13 However, these results were not reproduced. 15 The benefit of adding pexelizumab in the setting of STEMI is also controversial. In the COMMA trial, pexelizumab resulted in a statistically significant reduction in mortality but not in a reduction of infarct size assessed by creatine kinase MB. 12 The reduction of inflammatory markers, such as high-sensitivity C-reactive protein and interleukin 6, could explain this puzzling paradox. 18 However, the COMMA trial may represent the play of chance and have provided an ''optimistic'' conclusion. 12 Although probably underpowered given the low morbidity and mortality, the APEX-AMI trial was negative, suggesting no effect of pexelizumab on top of current therapies. 11 The low rate of adverse events in the APEX placebo arm was not foreseen, so it is conceivable that a treatment benefit was missed.
11
Our systematic review and meta-analysis shows that pexelizumab does not provide any clinical benefits in patients undergoing emergency reperfusion therapy for STEMI, whereas statistically and clinically significant benefits are derived in the setting of CABG as it reduces by almost one third the relative risk of death, with an estimated number needed to treat of 100.
The lack of benefit of pexelizumab in the setting of patients with STEMI contrasts with the apparent benefit observed in patients undergoing CABG. Such data, despite promising premises from experimental studies, emphasize the challenge of translating preliminary data into clinical practice. Animal models demonstrate increased accumulation of MAC (C5b-9) in reperfusion injury but stable levels of C5a during cardiopulmonary bypass. 19, 20 The latter suggests a possible pulmonary vascular sequestration of C5a-activated granulocyte resulting in the bypass-related neutropenia. 19, 20 Upstream delivery of pexelizumab before surgery may reduce the ''generalized'' inflammatory process accompanying cardiopulmonary bypass. On the other hand, once microvascular damage and myocardial death owing to necrosis, ''local'' inflammation, and apoptosis 21 have become irreversible in the setting of STEMI, complement activation is likely to have progressed to MAC formation, nullifying any benefit derived from the administration of pexelizumab ( Figure 6 ). Furthermore, penetration of pexelizumab into myocardial tissue may be limited owing to microvascular obstruction. Metabolic and inflammatory derangements have also been observed during both reperfusion therapy for STEMI and cardiopulmonary bypass. 19, 20 However, despite some similarities, the different effect of pexelizumab might reflect the presence of different activation pathways and/or magnitudes of activation of the complement cascade. AMI, Acute myocardial infarction; CABG, coronary artery bypass graft; CHF, congestive heart failure; MAE, major adverse events; STEMI, ST elevation myocardial infarction. A previous meta-analysis 22 suggested a beneficial effect on 30-day mortality in both clinical settings. Our independent, unfunded, and updated analysis differs significantly from the previous study in several ways. First, we did not include the bolus-only arms in the primary analysis, inasmuch as our sensitivity analysis demonstrated both increased heterogeneity and inconsistency by including this group. We included all the available data on the topic, assessing not only the risk of overall death but also that of other MAEs, including stroke and congestive heart failure. We performed a pre-specified analysis according to different clinical settings, showing an unexpected discrepancy in the usefulness of pexelizumab in patients with STEMI compared with those undergoing CABG. The reason that our findings differ from those of the previous study might be due to the addition of two large recent trials not included in the previous analysis. 11, 15 A limitation inherent to all meta-analyses is the potential heterogeneity among studies, in terms of protocols (eg, control treatments and length of follow-up), patients, and/or sample sizes. Such diversity may lead to inaccurate conclusions. However, both the Cochrane Q heterogeneity test (which assesses heterogeneity among ORs and the validity of pooling the results) and the test of inconsistency (I 2 ) indicated significant heterogeneity and inconsistency only for the overall analyses of MAE and death, possibly consistent with the diversity between trials evaluating pexelizumab in the STEMI or CABG setting. Moreover, the overall quality of included trials was good, thus confirming the robustness of the present meta-analysis.
Conclusion
The rationale and potential benefits of adding a C5 complement inhibitor to currently available therapy for STEMI and CABG surgery are attractive. Unfortunately, there appears to be no improvement in outcomes for patients undergoing reperfusion for STEMI. Alternatively, the benefit in patients undergoing on-pump CABG appears real and impressive, with a significant reduction in death. Figure 6 . Complement is a highly conserved innate immune cascade of several proteins interacting to recognize and destroy pathogens. According to the nature of the pathogen and/or the activating surface, three different activation pathways are known: classical, alternative, and lectin. The classical pathway is activated by the interaction of C1q with antibody-antigen complexes, but also with nonimmune molecules. The alternative pathway is activated by activating surfaces in the absence of immune complexes and leads to the deposition of C3 fragments on the target cells. The lectin pathway is activated by binding of mannan-binding lectin to carbohydrates expressed on pathogens but not on "self'' cells. The common end result of these pathways is either the opsonization or the destruction (through formation of the lytic molecule C5b-9, the membrane attack complex) of the target pathogen. The system is regulated by proteins such as fI, DAF, CR1, MCP. During cardiopulmonary bypass, the complement system is mainly activated by the alternative pathways. This leads to the generalized inflammatory process accompanying the bypass. Upstream delivery of pexelizumab might be efficacious as it inhibits the formation of MAC at an early stage, and also of C5a, a potent anaphylotoxin. In the STEMI setting the late delivery of pexelizumab, once the microvascular damage and myocardial death have become irreversible, might be ineffective as the MAC and C5a formation have been completed. Moreover, the microvascular disfunction can also limit the penetration of pexelizumab into the perinfarct area, where a localized inflammatory/apoptotic process is present. C, Complement component; DAF, decay accelerating factor; MAC, membrane attack complex; MASP, MBL-associated serine proteinase; MBL, mannan-binding lectin; MCP, membrane cofactor protein; STEMI, ST elevation myocardial infarction.
